Skip to content
DataLookout
Menu

BENRAPREDNCT04565483

Predictive Signature of Benralizumab Response

StatusCompleted
PhasePhase 4
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 9 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 4 words Show 6 more changesShow less
    • Trial completed
    • Final enrollment: 85 participants (planned 220)
    • Primary completion date changed from estimate of Oct 2026 to Aug 19, 2026
    • Secondary endpoints: details revised at 5 of 6 entries
    • Site details revised at 20 of 20 sites
    • Collaborators revised (2)
  2. Minor Site details revised at 3 of 20 sitesv9
  3. Minor Site details revised at 2 of 20 sitesv8
  4. Notable Primary completion date: Mar 2024 to Oct 2026
    • Study sites: 16 to 20
    • Study completion date: Apr 2024 to Nov 2026
    v7
  5. Notable Eligibility criteria shortened, about 38 words
    • Site details revised at 8 of 16 sites
    v6
Show 3 earlier versionsHide 3 earlier versions
  1. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 2021 to Oct 11, 2021
    • Site details revised at 16 of 16 sites
    v5
  2. Notable Start date: Dec 2020 to Oct 2021
    • Eligibility criteria shortened, about 6 words
    • Study sites: 15 to 16
    v4
  3. Notable Eligibility criteria expanded, about 17 words
    • Secondary endpoints revised (6)
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Predictive value of early blood gene expression signature of Benralizumab
Timeframe: 12 months

Secondary (6)

Molecular signature predictive of stabilization
The stability of the signature over time
The association of gene expression patterns
Association of gene expression patterns and clinical characteristics
Stratification value of gene expression in severe asthma
Show 1 moreShow less
Scenario-based cost-utility analysis

Arms and interventions

BENRALIZUMABExperimental

Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion at the inclusion visit. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.

Drugs: Benralizumab Prefilled Syringe

Sites

20 sites in 1 country